The Benefits of PROLASTIN-C Therapy
Since 1988, patients treated with PROLASTIN® have achieved target AAT levels in as little as 1 month.2
PROLASTIN-C is augmentation therapy
PROLASTIN-C is called augmentation therapy; it "augments" or replaces the AAT missing from your body. The effect of augmentation therapy on pulmonary exacerbations and on the rate of progression of emphysema has not been demonstrated in adequately powered, randomized, controlled clinical trials for any Alpha1-PI product.
In clinical trials, PROLASTIN-C was as effective as PROLASTIN at raising AAT levels.
PROLASTIN®-C is indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency). PROLASTIN-C is not approved for the treatment of emphysema due to other causes.1 PROLASTIN-C is not indicated for treatment of liver disease due to Alpha-1.
The most common drug-related adverse reaction observed at a rate of >5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.
PROLASTIN-C provides important patient conveniences
Shorter infusion volume and time compared to PROLASTIN
- approximately 15-minute infusion time when given at the recommended infusion rate
Easy product storage
- no refrigeration needed
PROLASTIN DIRECT® PATIENT SERVICES
One-stop PROLASTIN-C enrollment, delivery and support.
Prolastin Direct® Patient Services secures insurance authorization, coordinates infusion services, ships PROLASTIN-C directly to the location of your choice, and connects you to health management coordinators who are experienced Alpha-1 patients themselves. Find out more about Prolastin Direct® Patient Services now.